Search research articles
Contact Us
Filters
Showing results (1-10 of 12) with videos related to
Page
of 2
Sort By:
Drugs
|
February 12, 2025
From Prospective Evaluation to Practice: Model-Informed Dose Optimization in Oncology
Bram C Agema, Birgit C P Koch, Ron H J Mathijssen, et al.
Pharmacogenomics
|
December 13, 2019
Effects of pharmacogenetic variants on vemurafenib-related toxicities in patients with melanoma
Andrew Kl Goey, Mirjam de With, Bram C Agema, et al.
Cancers
|
July 2, 2021
Population Pharmacokinetics of Oxycodone and Metabolites in Patients with Cancer-Related Pain
Bram C Agema, Astrid W Oosten, Sebastiaan D T Sassen, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|
February 8, 2023
Toward model-informed precision dosing for tamoxifen: A population-pharmacokinetic model with a continuous CYP2D6 activity scale
Bram C Agema, Sanne M Buijs, Sebastiaan D T Sassen, et al.
Cancer Chemotherapy and Pharmacology
|
January 2, 2020
The influence of single-nucleotide polymorphisms on overall survival and toxicity in cabazitaxel-treated patients with metastatic castration-resistant prostate cancer
Bodine P S Belderbos, Mirjam de With, Rajbir K Singh, et al.
Clinical Pharmacokinetics
|
September 27, 2024
Selecting the Best Pharmacokinetic Models for a Priori Model-Informed Precision Dosing with Model Ensembling
Bram C Agema, Tolra Kocher, Ayşenur B Öztürk, et al.
Genes
|
April 2, 2020
Influence of Genetic Variation in <i>COMT</i> on Cisplatin-Induced Nephrotoxicity in Cancer Patients
Bram C Agema, Stijn L W Koolen, Mirjam de With, et al.
Journal of Pain and Symptom Management
|
August 30, 2024
Optimizing the Dosing Regimen During Rotation From Subcutaneous to Transdermal Administration of Fentanyl
Bram C Agema, Kim Vrielink, Esther Oomen-de Hoop, et al.
Therapeutic Advances in Medical Oncology
|
June 9, 2022
Improving the tolerability of osimertinib by identifying its toxic limit
Bram C Agema, G D Marijn Veerman, Christi M J Steendam, et al.
European Urology Oncology
|
November 4, 2023
Early Identification of Patients at Risk of Cabazitaxel-induced Severe Neutropenia
Bram C Agema, Stefan A J Buck, Mano Viskil, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 12) with videos related to
Sort By:
Page
of 2
Drugs
|
February 12, 2025
From Prospective Evaluation to Practice: Model-Informed Dose Optimization in Oncology
Bram C Agema, Birgit C P Koch, Ron H J Mathijssen, et al.
Pharmacogenomics
|
December 13, 2019
Effects of pharmacogenetic variants on vemurafenib-related toxicities in patients with melanoma
Andrew Kl Goey, Mirjam de With, Bram C Agema, et al.
Cancers
|
July 2, 2021
Population Pharmacokinetics of Oxycodone and Metabolites in Patients with Cancer-Related Pain
Bram C Agema, Astrid W Oosten, Sebastiaan D T Sassen, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|
February 8, 2023
Toward model-informed precision dosing for tamoxifen: A population-pharmacokinetic model with a continuous CYP2D6 activity scale
Bram C Agema, Sanne M Buijs, Sebastiaan D T Sassen, et al.
Cancer Chemotherapy and Pharmacology
|
January 2, 2020
The influence of single-nucleotide polymorphisms on overall survival and toxicity in cabazitaxel-treated patients with metastatic castration-resistant prostate cancer
Bodine P S Belderbos, Mirjam de With, Rajbir K Singh, et al.
Clinical Pharmacokinetics
|
September 27, 2024
Selecting the Best Pharmacokinetic Models for a Priori Model-Informed Precision Dosing with Model Ensembling
Bram C Agema, Tolra Kocher, Ayşenur B Öztürk, et al.
Genes
|
April 2, 2020
Influence of Genetic Variation in <i>COMT</i> on Cisplatin-Induced Nephrotoxicity in Cancer Patients
Bram C Agema, Stijn L W Koolen, Mirjam de With, et al.
Journal of Pain and Symptom Management
|
August 30, 2024
Optimizing the Dosing Regimen During Rotation From Subcutaneous to Transdermal Administration of Fentanyl
Bram C Agema, Kim Vrielink, Esther Oomen-de Hoop, et al.
Therapeutic Advances in Medical Oncology
|
June 9, 2022
Improving the tolerability of osimertinib by identifying its toxic limit
Bram C Agema, G D Marijn Veerman, Christi M J Steendam, et al.
European Urology Oncology
|
November 4, 2023
Early Identification of Patients at Risk of Cabazitaxel-induced Severe Neutropenia
Bram C Agema, Stefan A J Buck, Mano Viskil, et al.
Page
of 2